TCR² Therapeutics to Present at the J.P. Morgan Healthcare Conference

Rhea-AI Summary

TCR2 Therapeutics (Nasdaq: TCRR), a clinical-stage cell therapy company, announced that Garry Menzel, President and CEO, will present a company progress update at the 40th Annual J.P. Morgan Healthcare Conference on January 13, 2022, at 7:30 AM E.T. The presentation will be hosted virtually, and a live webcast can be accessed through the company's Investors page. An archived replay will be available for 30 days post-event, showcasing the company's advancements in novel T cell therapies targeting solid tumors.

CAMBRIDGE, Mass., Jan. 07, 2022 (GLOBE NEWSWIRE) -- https://investors.tcr2.com/

TCR² Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for cancer patients suffering from solid tumors, today announced that Garry Menzel, President and Chief Executive Officer of TCR² Therapeutics, will present an update on Company progress at the 40th Annual J.P. Morgan Healthcare Conference on Thursday, January 13, 2022 at 7:30AM E.T. using a virtual platform.

A live webcast of the presentation will be available on the Investors page of the Company’s website at www.investors.tcr2.com. An archived replay will be available for at least 30 days following the presentation.

About TCR² Therapeutics

TCR² Therapeutics Inc. is a clinical-stage cell therapy company developing a pipeline of novel T cell therapies for cancer patients suffering from solid tumors. The company is focused on the discovery and development of product candidates against novel and complex targets utilizing its proprietary T cell receptor (TCR) Fusion Construct T cells (TRuC^®-T cells). The TRuC platform is designed to specifically recognize and kill cancer cells by harnessing signaling from the entire TCR, independent of human leukocyte antigens (HLA). For more information about TCR², please visit www.tcr2.com.

Investor and Media Contacts:

TCR² Therapeutics

Carl Mauch
Director, Investor Relations and Corporate Communications
(617) 949-5667
carl.mauch@tcr2.com

FAQ

What time will TCRR present at the J.P. Morgan Healthcare Conference?

TCRR will present at 7:30 AM E.T. on January 13, 2022.

Where can I watch the TCRR presentation from the J.P. Morgan Healthcare Conference?

You can watch the TCRR presentation live on their Investors page.

How long will the archived presentation of TCRR be available?

The archived presentation will be available for at least 30 days after the event.

What is TCR2 Therapeutics focusing on?

TCR2 Therapeutics is focused on developing novel T cell therapies for cancer patients with solid tumors.

Who is the CEO of TCR2 Therapeutics?

Garry Menzel is the President and CEO of TCR2 Therapeutics.